Introduction {#S1}
============

There is an ongoing discussion on potential contributions of the peripheral and central nervous system (PNS, CNS) to the pathophysiology of pain in fibromyalgia syndrome (FMS). The CNS has been investigated with different methods pointing to an altered processing of nociceptive input in FMS patients compared to controls. Current evidence supports increased central sensitization, morphological alterations in cortical areas, reduced functional connectivity of descending pathways, and increased activity in the cerebral "pain matrix" ([@B3]; [@B4]). In a recent study, even a potential influence of central mechanisms on peripheral innervation was suggested in an experimental model ([@B8]).

Reduction in central opioid receptor binding has been described in FMS patients ([@B7]) and was confirmed in antinociceptive brain regions ([@B13]). In a previous study, we showed reduced systemic gene and protein expression of the anti-inflammatory and analgesic cytokine interleukin-4 (IL-4) in patients with FMS compared to healthy controls ([@B18]). IL-4 links the neuro-immune and the opioid system by inducing μ-opioid receptor gene transcription ([@B9]). We hypothesized that FMS patients with low systemic IL-4 gene expression might also have a reduced central opioid binding capacity, potentially leading to low opioid-sensitivity to endogenous and exogenous opioids as a contributor to FMS pain.

Subjects and Methods {#S2}
====================

Subjects {#S2.SS1}
--------

Our study was approved by the Ethics Committees of the Universities of Würzburg and Mainz, Germany. Written informed consent was obtained from all patients before inclusion. Patients were recruited at the Department of Neurology, University of Würzburg between 2007 and 2010. We enrolled seven opioid naïve FMS patients (1 man, 6 women) with a median age of 58 years (51--69 years) fulfilling the American College of Rheumatology 1990 diagnostic criteria ([@B21]) and who were willing to undergo experimental PET assessment in addition to the tests performed to investigate the PNS ([@B19]) and the CNS ([@B20]). Except for one patient, all patients were seen at three visits ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Inclusion criteria were: men and women ≥ 18 years, other possible differential diagnoses excluded (e.g., rheumatologic, orthopedic), no clinically relevant psychiatric disorder (examined by systematic psychiatric interview). Exclusion criteria were: pain of other origin than FMS (e.g., post-surgery pain), current or prior cerebral diseases (e.g., stroke, cerebral hemorrhage or head trauma), prior or current opioid intake.

Clinical Examination and Questionnaire Assessment {#S2.SS2}
-------------------------------------------------

Patients underwent complete neurological examination at the Department of Neurology, University of Würzburg, Germany by the same investigator (N.Ü.) and the diagnosis of FMS was confirmed ([@B21]). For standardized pain assessment we used the German version of the Neuropathic Pain Symptom Inventory (NPSI) and the Graded Chronic Pain Scale (GCPS). To investigate depressive symptoms, the German version of the Beck Depression Inventory II (BDI) was applied. The calculated BDI scores reflect \> 14 mild, \>20 medium, \>29 severe depressive symptoms. The German version of the Fibromyalgia Impact Questionnaire (FIQ) was used to determine FMS associated symptoms and their burden on overall well-being in the week before assessment. The FIQ was used instead of the revised FIQ, which was published after study initiation.

Blood Withdrawal and IL-4 Gene Expression Analysis {#S2.SS3}
--------------------------------------------------

Venous whole blood was withdrawn at 8--9 a.m. in monovettes containing ethylene-diamine-tetra-acetic acid after over-night fasting. A second blood sample was collected from six of the seven patients during a routine clinical follow-up visit (median latency 1.3 years after first visit) under the same conditions; of one patient blood could be obtained only during the second visit (see below). Aliquoted and flash-frozen (in liquid nitrogen) blood samples were stored at --80°C before further processing.

Gene expression analysis was performed as described earlier ([@B18]). mRNA was isolated from frozen blood samples using a guanidine thiocyanate containing kit (Roti Quick Kit^®^, Germany). Afterward, 750 ng of mRNA were reverse transcribed into cDNA with TaqMan Reverse Transcription Reagents^®^ (Applied Biosystems, Germany) and 5 μL cDNA each were used for gene expression analysis of IL-4. TaqMan Universal Master Mix^®^ (Applied Biosystems, Germany) and specific oligonucleotide primers for IL-4 (ID: Hs00174122_m1) and the endogenous control 18sRNA (ID: Hs99999901_s1) (Applied Biosystems, Germany) were applied. Each qRT-PCR reaction plate contained a calibrator sample, which was the blood sample of the control person whose threshold cycle(Ct)-value was next to the calculated mean of all control samples specific for each IL-4. Results were compared with values obtained from seven healthy control blood samples previously collected in our laboratory (1 man, 6 women; median age 57 years, range 31--76). Samples were measured as triplicates and data were evaluated with the comparative ΔΔCt-method.

PET Scans {#S2.SS4}
---------

### Data Acquisition {#S2.SS4.SSS1}

Within 4 weeks after clinical examination and blood withdrawal, PET scans were performed under resting conditions at the Department of Nuclear Medicine, University of Mainz, Germany using a Siemens EXACT PET scanner (Siemens/CTI, Knoxville, YN, United States) and the subtype-non-selective opioidergic radioligand \[F-18\]fluoroethyl-diprenorphine (\[18F\]FEDPN) as previously described ([@B1]). Dynamic emission imaging in 3D-mode started simultaneously with \[18F\]FEDPN injection (185 ± 6 MBq) and had a total duration of 94 min. The recordings were scatter and attenuation corrected and then reconstructed with filtered back projection (FBP) using Hanning-Filter with a filter width of 7.3 mM.

### Data Assessment {#S2.SS4.SSS2}

Parametric images of the non-displaceable binding potential as a parameter of regional cerebral opioid receptor availability were computed using the non-invasive Logan Plot with the occipital cortex as reference region. Previously scanned eleven healthy subjects (5 men, 6 women; median age 42 years, range 30--50 years) served as a normal control group using the same acquisition, reconstruction, and quantitation protocols.

Statistical Analysis {#S2.SS5}
--------------------

Statistical analysis of the non-normally distributed qRT-PCR data was performed using SPSS software version 24 (IBM, Ehningen, Germany), and the non-parametric Mann-Whitney-*U*-test was applied. Significance was assumed at *p* \< 0.05. Statistical analysis of the PET data was performed using SPM8 implemented in Matlab 7.9 (MathWorks, Sherborn, MA, United States). The analysis included several steps. First, one-way analysis of covariance (ANCOVA), controlling for global \[18F\]FEDPN binding potential and followed by *post hoc* unpaired *t*-tests, was used to identify significant differences in binding potential between the normal healthy controls and the opioid naïve FMS patients. The resulting set of values for each contrast constituted a statistical parametric map of t statistics (SPMt). The SPMt values were transformed to the unit normal distribution SPMz. To correct for multiple comparisons, SPMt offers the method of small volume correction (SVC). We performed SVC for a number of 1,500 voxels leading to a corrected *p* \< 0.05. The statistical parametric maps for intergroup comparisons were based on a threshold for uncorrected probability of *p* \< 0.005.

Results {#S3}
=======

Clinical Findings {#S3.SS1}
-----------------

Neurological examination was normal in all patients at both visits. The [Table 1](#T1){ref-type="table"} and [Supplementary Table S2](#TS2){ref-type="supplementary-material"} summarize the group and individual characteristics of the study population at the second visit (i.e., prior to PET scan assessment). All patients had chronic and constant pain with a median current pain intensity of 5 (range 3--7) on a numeric rating scale (NRS) ranging from zero (no pain) to ten (worst pain).

###### 

Clinical characteristics of study cohort.

  M, F                            1, 6
  ------------------------------- -------------
  Age (years)                     58 (51--69)
  Disease duration (years)        36 (20--45)
  NPSI sum score                  24 (13--70)
  Current pain intensity (GCPS)   4 (3--7)
  Overall pain intensity (GCPS)   60 (57--73)
  Impairmant due to pain (GCPS)   2 (0--4)
  BDI score                       11 (7--30)
  FIQ sum score                   48 (30--68)

Median values are given with ranges in brackets. BDI, Beck Depression Inventory; F, female; FIQ, Fibromyalgia Impact Questionnaire; GCPS, Graded Chronic Pain Scale; M, male; NPSI, Neuropathic Pain Symptom Inventory.

Systemic IL-4 Gene Expression Remains Stable Over Time {#S3.SS2}
------------------------------------------------------

IL-4 gene expression was detectable in blood samples of all patients who had a blood withdrawal at both visits. Gene expression levels remained stable over time ([Figure 1A](#F1){ref-type="fig"}). In an exploratory approach, we normalized the obtained qRT-PCR data of our healthy control group to "1." Relative IL-4 gene expression in blood samples was \< 1 ("low") in four patients and \> 1 ("high") in three patients ([Supplementary Table S3](#TS3){ref-type="supplementary-material"} and [Figure 1B](#F1){ref-type="fig"}). PET scan data were stratified to the entire FMS patient group compared to laboratory normative values and for low and high IL-4 gene expression.

![Interleukin-4 (IL-4) gene expression in blood samples. Graphs show the relative gene expression of IL-4 in whole blood samples of patients with fibromyalgia syndrome (FMS) compared to healthy controls. **(A)** Gene expression does not differ between visit 1 and 2. **(B)** At both visits the FMS group comprised patients with low and high IL-4 gene expression compared to healthy controls. The difference became significant at visit 1 comparing patients with high IL-4 expression with controls (\**p* \< 0.05).](fnins-14-00512-g001){#F1}

Cerebral Opioid Binding Is Lower in FMS Patients Than in Healthy Controls {#S3.SS3}
-------------------------------------------------------------------------

When comparing PET scans of all FMS patients with data of healthy controls (eleven healthy subjects previously scanned using the same acquisition, reconstruction, and quantitation protocols), the opioid binding capacity was lower in patients with FMS in the mid cingulate cortex (MNI coordinates (x,y,z): \[14/ -- 14/38\]; *z* = 3.08, cluster size 66 voxels; threshold: *p* \< 0.005; [Figure 2A](#F2){ref-type="fig"}). Using a threshold of *p* \< 0.005, we found an increased binding potential in the fronto-basal cortex of FMS patients with higher systemic IL-4 gene expression compared to those with low IL-4 gene expression (rectal gyrus, MNI coordinates (x,y,z): \[--6/22/ --24\], *z* = 3.60, cluster size 259 voxels; [Figure 2B](#F2){ref-type="fig"}).

![Cerebral opioid receptor binding potential in the entire patient group and after stratification for systemic interleukin-4 (IL-4) expression. **(A)** Patients with fibromyalgia syndrome (FMS) showed reduced opioid receptor binding potential (blue) in mid cingulate cortex (*z* = 3.08) compared to healthy controls (blue area; threshold *p* \< 0.005 corresponding to a z-score of 2.58). **(B)** Patients with high IL-4 gene expression showed increased opioid receptor binding potential (red) in fronto-basal cortex (rectal gyrus, *z* = 3.60) compared to FMS patients with low IL-4 expression (red area; *p* \< 0.005, *z* = 2.58). Scale bars represent z-scores.](fnins-14-00512-g002){#F2}

Discussion {#S4}
==========

We investigated the cerebral opioid receptor availability of FMS patients compared to healthy controls and confirm previous findings showing reduced \[18F\]FEDPN binding in FMS patients ([@B7]; [@B13]). Despite the small number of study participants, our data also imply a potential link between IL-4 gene expression and cerebral opioid receptor binding potential.

Opioids exert analgesic effects in only a subgroup of patients with FMS and are not recommended by national and international treatment guidelines as first line medication. A reduction in central opioid receptor binding has been reported in FMS patients particularly in antinociceptive brain regions. Harris et al. investigated 17 patients with FMS compared to 17 healthy controls with PET scans and reported reduced cerebral μ-opioid receptor availability in patients ([@B7]). The same group later assessed 18 FMS patients and compared pain-evoked functional magnetic resonance imaging data with endogenous μ-opioid receptor binding ([@B13]). The authors observed reduced μ-opioid receptor availability associated with decreased pain-evoked neural activity, suggestive of dysfunction of the endogenous opioid system as one central contributor to FMS related pain. Interestingly, even in our small cohort, we could confirm the finding of reduced cerebral opioid receptor availability in the mid cingulate cortex, and, like in [@B7], the findings were lateralized to the right.

Our data on a potential link with systemic IL-4 gene expression levels extend this finding by an interesting neuro-immune connection, which includes a potential role of IL-4 linking the opioid and immune system. IL-4 expression has been investigated in several chronic pain syndromes. In patients with FMS, systemic IL-4 gene and protein expression was reduced compared to controls ([@B18]; [@B14]). Lower IL-4 levels were found in patients with painful compared to painless polyneuropathies ([@B16]) and in complex regional pain syndrome ([@B15]). Confirming a role of IL-4 in pain modulation, IL-4 deficient mice are characterized by mechanical hypersensitivity, over-expression of pro-inflammatory cytokines ([@B17]) and neuronal hyperexcitability ([@B10]). Former ([@B6]) and recent reports ([@B5]; [@B12]; [@B2]; [@B11]) strengthen the evidence for a high analgesic potential of IL-4. While systemic pro- and anti-inflammatory cytokine expression does not reflect acute pain intensity, further exploring the link between IL-4 and the opioid system ([@B9]) may give important insights into the pathophysiology of chronic pain.

The major limitation of our study is the low number of participants. Two reasons hampered patient recruitment: history or current intake of opioid analgesics, which were exclusion criteria, and the refusal of patients to undergo experimental PET using nuclear tracers. Also, no PET scans were available from the control persons in whom systemic IL-4 levels were investigated, thus \[18F\]FEDPN binding and its correlation with IL-4 levels could not be assessed in these. Matching of FMS patients and healthy controls was not possible for PET experiments, which is another limitation. We found a cluster in the fronto-basal cortex with a max *z* = 3.6 (259 voxels). Analysis of this cluster showed more voxels in gray matter (101) than in white matter (37). There are two effects which may impact the spatial precision of significant clusters: the limited spatial resolution of the PET images compared to MRI, which is used for overlay to identify the corresponding anatomic structure, and additional smoothing of PET images prior to SPM analysis, which is required to achieve a reasonable statistical power. It is, however, intriguing that differences in the opioid receptor binding potential were found between groups despite this low number of subjects.

Data Availability Statement {#S5}
===========================

All datasets generated for this study are included in article/[Supplementary Material](#TS1){ref-type="supplementary-material"}.

Ethics Statement {#S6}
================

The studies involving human participants were reviewed and approved by the Ethics Committees of the Universities of Würzburg and Mainz, Germany. The patients/participants provided their written informed consent to participate in this study.

Author Contributions {#S7}
====================

NÜ and CS: study concept and design. NÜ, H-GB, SK, and S-JA: acquisition of data. NÜ, H-GB, MS, FB, and CS: analysis and Interpretation of data.

Conflict of Interest {#conf1}
====================

NÜ: speaker honoraria and research grants from Biogen, Grifols, Sanofi Genzyme, Shire Takeda. FB: speaker honoraria from Akcea, Pfizer, and Alnylam in the past three years. CS: consulting fees and speaker honoraria from Air Liquide, Akcea, Algiax, Alnylam, CSL Behring, Novartis, Pfizer, Sanofi Genzyme, Takeda, UCB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** The study was supported by intramural funds of the Universities of Würzburg and Mainz, Germany. This publication was supported by the Open Access Publication Fund of the University of Würzburg. NÜ was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; UE171/5-1).

We thank Lydia Biko and Rainer Marx for help during patient recruitment and Sonja Gommersbacher and Daniela Urlaub for expert technical help.

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnins.2020.00512/full#supplementary-material>

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

[^1]: Edited by: Francisco Ciruela, University of Barcelona, Spain

[^2]: Reviewed by: Richard E. Harris, Michigan Medicine, University of Michigan, United States; Kristoffer Sahlholm, Umeå University, Sweden

[^3]: ^†^These authors share senior authorship

[^4]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
